OBJECTIVE: The aim of this study was to develop chronotherapeutic drug delivery system of indomethacin using polyethylene oxide (PEO) with a predetermined lag time of 6 h by compression coating technique. MATERIALS AND METHODS: Solid dispersions (SD) of indomethacin were prepared using novel carrier sucrose fatty acid ester (SFE 1815) to increase the in vitro dissolution. The optimized SD was formulated as immediate release core tablet which were further coated with PEO (WSR Coagulant or WSR N12 K) using compression coating technique. Compression coated tablets formulated with PEO WSR Coagulant in 1:1.7 ratio of core tablet weight and coating polymer was considered as optimized formulation, which was further characterized by differential scanning calorimetry, X-ray diffractometry, Fourier transformed infrared spectroscopy, and scanning electron microscopy. RESULTS: The results indicated that there was no chemical incompatibility and slight change in surface properties. C(max), area under the curve (AUC(0-t)), and T(max) following oral ingestion of commercial capsule (Indocap) and optimized formulation (CT 4) were found to be 1973.18 ± 36.89 ng/mL, 11090.09 ± 131.21 ng/mL/h, 0.99 ± 0.02 h and 2115.46 ±6 2.61, 10413.14 ± 299.66 ng/mL/h, 7.00±0.02 h, respectively. CONCLUSION: Unaltered AUC(0-t) and C(max), but delayed T(max) indicated clear lag time before immediate release of drug which is suitable for treating rheumatoid arthritis following circadian rhythm.
OBJECTIVE: The aim of this study was to develop chronotherapeutic drug delivery system of indomethacin using polyethylene oxide (PEO) with a predetermined lag time of 6 h by compression coating technique. MATERIALS AND METHODS: Solid dispersions (SD) of indomethacin were prepared using novel carrier sucrose fatty acid ester (SFE 1815) to increase the in vitro dissolution. The optimized SD was formulated as immediate release core tablet which were further coated with PEO (WSR Coagulant or WSR N12 K) using compression coating technique. Compression coated tablets formulated with PEO WSR Coagulant in 1:1.7 ratio of core tablet weight and coating polymer was considered as optimized formulation, which was further characterized by differential scanning calorimetry, X-ray diffractometry, Fourier transformed infrared spectroscopy, and scanning electron microscopy. RESULTS: The results indicated that there was no chemical incompatibility and slight change in surface properties. C(max), area under the curve (AUC(0-t)), and T(max) following oral ingestion of commercial capsule (Indocap) and optimized formulation (CT 4) were found to be 1973.18 ± 36.89 ng/mL, 11090.09 ± 131.21 ng/mL/h, 0.99 ± 0.02 h and 2115.46 ±6 2.61, 10413.14 ± 299.66 ng/mL/h, 7.00±0.02 h, respectively. CONCLUSION: Unaltered AUC(0-t) and C(max), but delayed T(max) indicated clear lag time before immediate release of drug which is suitable for treating rheumatoid arthritis following circadian rhythm.
Authors: Hibah M Aldawsari; N Raghavendra Naveen; Nabil A Alhakamy; Prakash S Goudanavar; Gsn Koteswara Rao; Roja Rani Budha; Anroop B Nair; Shaimaa M Badr-Eldin Journal: Drug Deliv Date: 2022-12 Impact factor: 6.819